Teva Pharmaceuticals USA, Inc Recalls

2 recalls found for Teva Pharmaceuticals USA, Inc — spanning April 2026 through April 2026.

Medications: 2

The recalls listed below are active notices associated with Teva Pharmaceuticals USA, Inc in the FDA, NHTSA, USDA, and CPSC databases. None of the current recalls are classified as urgent. The current recalls involve sterility concerns. Check the specific lot numbers, model numbers, or production date codes in each notice carefully — a recall typically covers specific production runs, not everything a manufacturer sells.

A manufacturer appearing in the recall database does not indicate an ongoing safety failure. High-volume companies with large product lines naturally appear more frequently. What matters is whether your specific product — identified by lot number, model number, or date code — is included in a recall notice.

Browse all medication recalls
NoticeMedications

Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kits containing: 8-mL

Teva Pharmaceuticals USA, Inc

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

View recall →
NoticeMedications

Claravis (isotretinoin capsule, USP), 10 mg, Packaged as a) 100-count carton, NDC 0555-1054-56, with 10x10 blister packs

Teva Pharmaceuticals USA, Inc

Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin

View recall →